Makes and markets generic and branded specialty pharmaceuticals, including rare disease drugs.
Makes and markets generic and branded specialty pharmaceuticals, including rare disease drugs.
Earns from three sources: generic drugs, often hard-to-make or niche, sold to wholesalers and pharmacies; brands led by Cortrophin Gel, a corticotropin drug doctors use for flare-ups in conditions such as arthritis and lupus; and manufacturing for other drugmakers. The 2024 purchase of Alimera Sciences added eye-care products.
Moat: narrow (regulatory licence, distribution, scale). Diversified generics base plus a growing branded rare-disease franchise with regulatory exclusivity.
Headquarters: Baudette, Minnesota, US · Founded: 1993 · Employees: 970
Size ANI Pharmaceuticals (ANIP) is a United States Health Care company (Biotechnology) with a market value of $1.62B, the 1907th largest of 3,085 United States companies the cockpit tracks. Shares closed at $71.47 on 18 Nov 2026.
Performance Over six months the shares fell 12.8%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 25.9% over the last twelve months (peer median +23.4%); the operating margin is 15.3% (peer median 3.4%).
Valuation It trades at 7.5× forward earnings against a peer median of 37.0× (2nd cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +33%, so the hurdle is -41 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.7 points above its cost of capital (6.8% WACC).
Credit ANI Pharmaceuticals has 1 bond outstanding ($316M).
Short interest Short interest is 15.6% of the free float (30 Oct 2026).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.04B | $883M | $614M | $487M | $316M |
| Revenue growth | — | +44% | +26% | +54% | — |
| Gross profit | $553M | $451M | $296M | $246M | $121M |
| EBITDA | $242M | $173M | $69.9M | $109M | $31.2M |
| Net income | $109M | $71.4M | -$18.5M | $18.8M | -$47.9M |
| Free cash flow | $205M | $171M | $47.8M | $110M | -$40.1M |
| Capital expenditure | $29.3M | $34.3M | $17.0M | $18.5M | $16.5M |
| Total debt | $607M | $628M | $649M | $315M | $289M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ANI Pharmaceuticals ANIP | $1.62B | -13% | +26% | 15% | 7.5× | -7.6% |
| Amneal Pharmaceuticals AMRX | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ANIP | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.6% | -8.0% | 8th highest of 21 |
| 6-month return | -12.8% | -4.6% | 9th lowest of 20 |
| Distance from 52-week high | -18.6% | -44.5% | 2nd highest of 21 |
| Revenue growth (TTM) | +25.9% | +23.4% | 8th highest of 19 |
| Operating margin | 15.3% | 3.4% | 7th highest of 19 |
| Forward P/E | 7.5× | 37.0× | 2nd cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -7.6% | 33.0% | 2nd least demanding of 4 |
| Growth delivered (Del g) | +33.5% | +16.8% | highest of 4 |
| Hurdle (Req g minus delivered) | -41.1 pp | +8.1 pp | least demanding of 4 |
| ROIC minus cost of capital | +8.7 pp | -5.9 pp | 3rd highest of 15 |
| EV / EBITDA | 7.4× | 19.5× | 2nd cheapest of 6 |
| Net debt / EBITDA | 0.7× | -0.9× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 7.5× | -7.6% | +33.5% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 22.6× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 73.2× | 33.2% | +16.8% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 27.6× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 52.1× | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% | +15.0% |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 51.9× | 33.0% | +24.8% |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | n/a | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | 46.4× | n/a | n/a |
ANI Pharmaceuticals has 1 bond outstanding with $316M face value.